MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application

Linsey J. F. Peters, Juergen Floege, Erik A. L. Biessen, Joachim Jankowski, Emiel P. C. van der Vorst*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

22 Citations (Web of Science)

Abstract

There are still major challenges regarding the early diagnosis and treatment of chronic kidney disease (CKD), which is in part due to the fact that its pathophysiology is very complex and not clarified in detail. The diagnosis of CKD commonly is made after kidney damage has occurred. This highlights the need for better mechanistic insight into CKD as well as improved clinical tools for both diagnosis and treatment. In the last decade, many studies have focused on microRNAs (miRs) as novel diagnostic tools or clinical targets. MiRs are small non-coding RNA molecules that are involved in post-transcriptional gene regulation and many have been studied in CKD. A wide array of pre-clinical and clinical studies have highlighted the potential role for miRs in the pathogenesis of hypertensive nephropathy, diabetic nephropathy, glomerulonephritis, kidney tubulointerstitial fibrosis, and some of the associated cardiovascular complications. In this review, we will provide an overview of the miRs studied in CKD, especially highlighting miR-103a-3p, miR-192-5p, the miR-29 family and miR-21-5p as these have the greatest potential to result in novel therapeutic and diagnostic strategies.

Original languageEnglish
Article number6547
Number of pages31
JournalInternational journal of molecular sciences
Volume21
Issue number18
DOIs
Publication statusPublished - Sep 2020

Keywords

  • MicroRNAs
  • kidney fibrosis
  • chronic kidney disease
  • clinical application
  • PROMOTES RENAL FIBROSIS
  • DIABETIC-NEPHROPATHY
  • DOWN-REGULATION
  • COLLAGEN EXPRESSION
  • HIGH GLUCOSE
  • MESENCHYMAL TRANSITION
  • CARDIORENAL SYNDROME
  • ANGIOTENSIN-II
  • MOUSE MODEL
  • AKT KINASE

Cite this